Axsome Therapeutics (NASDAQ:AXSM) CEO Herriot Tabuteau Sells 20,163 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 20,163 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $146.94, for a total value of $2,962,751.22. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,062,229.26. The trade was a 73.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Herriot Tabuteau also recently made the following trade(s):

• On Thursday, December 4th, Herriot Tabuteau sold 10,558 shares of Axsome Therapeutics stock. The stock was sold at an average price of $148.18, for a total value of $1,564,484.44.
• On Tuesday, December 2nd, Herriot Tabuteau sold 49,252 shares of Axsome Therapeutics stock. The shares were sold at an average price of $144.59, for a total value of $7,121,346.68.
• On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The shares were sold at an average price of $133.79, for a total value of $6,750,909.61.
• On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The stock was sold at an average price of $134.49, for a total transaction of $2,928,519.75.
• On Monday, November 3rd, Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock. The shares were sold at an average price of $132.34, for a total transaction of $12,136,239.70.
• On Tuesday, October 7th, Herriot Tabuteau sold 13,390 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.77, for a total transaction of $1,590,330.30.
• On Wednesday, October 8th, Herriot Tabuteau sold 12,774 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.84, for a total transaction of $1,518,062.16.
• On Monday, October 6th, Herriot Tabuteau sold 19,220 shares of Axsome Therapeutics stock. The shares were sold at an average price of $120.17, for a total transaction of $2,309,667.40.
• On Tuesday, September 16th, Herriot Tabuteau sold 19,719 shares of Axsome Therapeutics stock. The shares were sold at an average price of $114.19, for a total transaction of $2,251,712.61.
• On Friday, September 12th, Herriot Tabuteau sold 27,907 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.96, for a total transaction of $3,319,816.72.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $150.01 on Friday. The firm has a market cap of $7.56 billion, a P/E ratio of -32.12 and a beta of 0.48. Axsome Therapeutics, Inc. has a 52-week low of $75.56 and a 52-week high of $152.94. The business’s 50-day moving average price is $134.32 and its 200 day moving average price is $118.51. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company had revenue of $170.99 million for the quarter, compared to analysts’ expectations of $162.96 million. The firm’s revenue was up 63.2% on a year-over-year basis. On average, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on AXSM shares. HC Wainwright lifted their price objective on shares of Axsome Therapeutics from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Mizuho increased their price objective on Axsome Therapeutics from $200.00 to $202.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Morgan Stanley boosted their target price on shares of Axsome Therapeutics from $194.00 to $196.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $154.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, November 4th. Finally, Wells Fargo & Company decreased their price objective on shares of Axsome Therapeutics from $163.00 to $157.00 and set an “overweight” rating on the stock in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $179.88.

Hedge Funds Weigh In On Axsome Therapeutics

Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in Axsome Therapeutics by 55.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 203,632 shares of the company’s stock valued at $21,257,000 after buying an additional 72,609 shares during the period. Jump Financial LLC bought a new position in Axsome Therapeutics during the first quarter worth $10,805,000. Nuveen LLC bought a new stake in Axsome Therapeutics in the first quarter valued at approximately $48,185,000. Swiss National Bank grew its stake in Axsome Therapeutics by 6.9% in the second quarter. Swiss National Bank now owns 65,200 shares of the company’s stock valued at $6,806,000 after acquiring an additional 4,200 shares during the period. Finally, Los Angeles Capital Management LLC grew its stake in Axsome Therapeutics by 154.5% in the second quarter. Los Angeles Capital Management LLC now owns 4,424 shares of the company’s stock valued at $462,000 after acquiring an additional 2,686 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.